Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-Arm Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Chemotherapy as Neoadjuvant Therapy for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma

NCT06908382 is registered in ClinicalTrials.gov with Shandong Provincial Hospital as lead sponsor.

NCT NCT06908382
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06908382 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-Arm Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Chemotherapy as Neoadjuvant Therapy for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma
Lead sponsor
Shandong Provincial Hospital
Phase
Phase 2
Overall status
Recruiting
Start date
April 28, 2025
Completion date
December 31, 2028
Enrollment
32 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced resectable esophageal squamous cell carcinoma